Lys - Model Glunomab / Glunozumab - Monoclonal Antibody

Glunomab / Glunozumab® monoclonal antibody, a groundbreaking mechanism of action:
In the pathophysiology of neurological diseases such as stroke, multiple sclerosis as well as many other neurodegenerative disorders, one protease called tissue plasminogen activator (tPA) is triggering off-target toxicity via the binding to NMDA receptors (NMDAr) present on vascular endothelial cells and neurons, leading to its consequent hyperactivation and causing deleterious increase of the permeability of the blood brain barrier, as well as strong neuroinflammation and excitotoxicity.

By blocking the tPA-NMDAr interaction, Glunomab / Glunozumab® counteracts this tPA-dependent strong toxicity, without interfering with physiological NMDAr functioning.

A systemic drug treatment for CNS pathologies:

• Target : NMDA receptors (NMDAr) present on vascular endothelial cells (within the blood vessels)
• Strong advantage : no need to cross the blood brain barrier (BBB) to act on the central nervous system (CNS)

A very high specificity:

• The epitope is only present on NMDA receptors (GluN1 subunit), not on any other proteins, and is fully conserved among species

A fully characterized mechanism of action:

• MoA: antagonism of tPA-NMDAr interaction in the blood vessels, leading to restoration of NMDAr physiological functioning (no perturbation of NMDAr).

Therapeutic effects on blood brain barrier permeability and associated neuroinflammation and excitotoxicity